Recent developments in constitutive receptor activity and inverse agonism, and their potential for GPCR drug discovery

Trends in Pharmacological Sciences

Volumn 27, Issue 2, 2006, Pages 92-96

  Bond, Richard A ^a   Ijzerman, Ad P ^b  

^a UNIVERSITY OF HOUSTON   (United States)

^b LEIDEN UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ATOSIBAN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BUCINDOLOL; BURIMAMIDE; CANDESARTAN; CETIRIZINE; CLOZAPINE; FAMOTIDINE; G PROTEIN COUPLED RECEPTOR; HALOPERIDOL; IRBESARTAN; LORATADINE; LOSARTAN; METOPROLOL; MONTELUKAST; OLANZAPINE; PHOSPHODIESTERASE INHIBITOR; PIRENZEPINE; PRAZOSIN; RANITIDINE; TERAZOSIN; TRIHEXYPHENIDYL; ZAFIRLUKAST;

DRUG DESIGN; DRUG INDUSTRY; DRUG MARKETING; DRUG SCREENING; HUMAN; NONHUMAN; PHARMACOGENETICS; PHARMACOLOGY; PRIORITY JOURNAL; REVIEW;

ALTERNATIVE SPLICING; ANIMALS; ANTIBODIES; AUTOANTIBODIES; DRUG DESIGN; HUMANS; MUTATION; POLYMORPHISM, GENETIC; RECEPTORS, G-PROTEIN-COUPLED;

EID: 31844446495     PISSN: 01656147     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tips.2005.12.007     Document Type: Review

References (58)

1. T. Costa, and A. Herz Antagonists with negative intrinsic activity at delta opioid receptors coupled to GTP-binding proteins Proc. Natl. Acad. Sci. U. S. A. 86 1989 7321 7325
2. 2-adrenergic receptor. Extending the ternary complex model J. Biol. Chem. 268 1993 4625 4636
3. P. Leff The two-state model of receptor activation Trends Pharmacol. Sci. 16 1995 89 97
4. T. Costa, and S. Cotecchia Historical review: Negative efficacy and the constitutive activity of G-protein-coupled receptors Trends Pharmacol. Sci. 26 2005 618 624
5. P. Chidiac Inverse agonist activity of beta-adrenergic antagonists Mol. Pharmacol. 45 1994 490 499
6. 2C receptors reveal novel inverse agonist activity of receptor ligands J. Biol. Chem. 269 1994 11687 11690
7. L.M. Leeb-Lundberg Antagonists of bradykinin that stabilize a G-protein-uncoupled state of the B2 receptor act as inverse agonists in rat myometrial cells J. Biol. Chem. 269 1994 25970 25973
8. R. Hanf Agonist-independent effects of muscarinic antagonists on Ca2+ and K+ currents in frog and rat cardiac cells J. Physiol. 461 1993 743 765
9. T. Kenakin Efficacy as a vector: the relative prevalence and paucity of inverse agonism Mol. Pharmacol. 65 2004 2 11
10. G. Milligan Constitutive activity and inverse agonists of G protein-coupled receptors: a current perspective Mol. Pharmacol. 64 2003 1271 1276
11. A. Wise The identification of ligands at orphan G-protein coupled receptors Annu. Rev. Pharmacol. Toxicol. 44 2004 43 66
12. M.R. Lerner Tools for investigating functional interactions between ligands and G-protein-coupled receptors Trends Neurosci. 17 1994 142 146
13. J. Stables A bioluminescent assay for agonist activity at potentially any G-protein-coupled receptor Anal. Biochem. 252 1997 115 126
14. J.N. Bresnick Identification of signal transduction pathways used by orphan G protein-coupled receptors Assay Drug Dev Technol 1 2003 239 249
15. G. Chen Use of constitutive G protein-coupled receptor activity for drug discovery Mol. Pharmacol. 57 2000 125 134
16. D.T. Chalmers, and D.P. Behan The use of constitutively active GPCRs in drug discovery and functional genomics Nat. Rev. Drug Discov. 1 2002 599 608
17. J.L. Scragg Constitutive activity of endogenous receptors by inducible Gq overexpression Biochem. Biophys. Res. Commun. 331 2005 1239 1244
18. 2 receptor with physiological constitutive activity Biochem. Biophys. Res. Commun. 173 1990 1169 1178
19. M.W. Beukers, and A.P. IJzerman How to boost GPCR mutagenesis studies using yeast Trends Pharmacol. Sci. 26 2005 533 539
20. A.J. Brown The orphan G protein-coupled receptors GPR41 and GPR43 are activated by propionate and other short chain carboxylic acids J. Biol. Chem. 278 2003 11312 11319
21. K.P. Minneman Splice variants of G protein-coupled receptors Mol. Interv. 1 2001 108 116
22. 3 receptor drugs Nat. Rev. Drug Discov. 4 2005 107 120
23. 3 receptors regulates histamine neurons in brain Nature 408 2000 860 864
24. 4 receptor splice variants show marked constitutive activity: role of the C-terminal intracellular domain Mol. Pharmacol. 55 1999 910 920
25. B.K. Rana Genetic variations and polymorphisms of G protein-coupled receptors: functional and therapeutic implications Annu. Rev. Pharmacol. Toxicol. 41 2001 593 624
26. A. Lee Distribution analysis of nonsynonymous polymorphisms within the G-protein-coupled receptor gene family Genomics 81 2003 245 248
27. C. Wahlestedt Lower rate of genomic variation identified in the trans-membrane domain of monoamine sub-class of human G-protein coupled receptors: the human GPCR-DB Database BMC Genomics 5 2004 91
28. M.C. Levin The myocardium-protective Gly-49 variant of the beta 1-adrenergic receptor exhibits constitutive activity and increased desensitization and down-regulation J. Biol. Chem. 277 2002 30429 30435
29. 2C receptor function by Cys23Ser, an abundant, naturally occurring amino-acid substitution Mol. Psychiatry 9 2004 55 64
30. C. Parnot Lessons from constitutively active mutants of G protein-coupled receptors Trends Endocrinol. Metab. 13 2002 336 343
31. 2C receptor silences constitutive activity J. Biol. Chem. 274 1999 9472 9478
32. 2C receptor isoforms J. Biol. Chem. 279 2004 2945 2954
33. R.A. de Ligt Inverse agonism at G protein-coupled receptors: (patho)physiological relevance and implications for drug discovery Br. J. Pharmacol. 130 2000 1 12
34. D. Dragun Angiotensin II type 1-receptor activating antibodies in renal-allograft rejection N. Engl. J. Med. 352 2005 558 569
35. 2-adrenoceptor antibody behave as antagonists Mol. Pharmacol. 58 2000 373 379
36. 2-adrenergic receptor J. Biol. Chem. 278 2003 36740 36747
37. 2 receptor antibody fragments J. Biol. Chem. 279 2004 55697 55706
38. R. Seifert, and K. Wenzel-Seifert Constitutive activity of G-protein-coupled receptors: cause of disease and common property of wild-type receptors Naunyn Schmiedebergs Arch. Pharmacol. 366 2002 381 416
39. S. Kosugi Characterization of heterogeneous mutations causing constitutive activation of the luteinizing hormone receptor in familial male precocious puberty Hum. Mol. Genet. 4 1995 183 188
40. G. Milligan, and R.A. Bond Inverse agonism and the regulation of receptor number Trends Pharmacol. Sci. 18 1997 468 474
41. MERIT-HF Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF) Lancet 353 1999 2001 2007
42. S.D. Thackray Clinical trials update: highlights of the scientific sessions of the American Heart Association year 2000: Val HeFT, COPERNICUS, MERIT, CIBIS-II, BEST, AMIOVIRT, V-MAC, BREATHE, HEAT, MIRACL, FLORIDA, VIVA and the first human cardiac skeletal muscle myoblast transfer for heart failure Eur. J. Heart Fail. 3 2001 117 124
43. E.J. Eichhorn Experience with beta blockers in heart failure mortality trials Clin. Cardiol. 22 Suppl. 5 1999 V21 V29
44. C. Maack Different intrinsic activities of bucindolol, carvedilol and metoprolol in human failing myocardium Br. J. Pharmacol. 130 2000 1131 1139
45. Z. Callaerts-Vegh Effects of acute and chronic administration of beta-adrenoceptor ligands on airway function in a murine model of asthma Proc. Natl. Acad. Sci. U. S. A. 101 2004 4948 4953
46. 2C receptors by chronic ligand exposure Eur. J. Pharmacol. 498 2004 59 69
47. 1B-adrenoceptors Naunyn Schmiedebergs Arch. Pharmacol. 363 2001 34 39
48. E.S. Burstein Pharmacology of muscarinic receptor subtypes constitutively activated by G proteins Mol. Pharmacol. 51 1997 312 319
49. 1 receptor antagonists Eur. J. Pharmacol. 387 2000 R5 R7
50. 1-receptor antagonists J. Med. Chem. 46 2003 5812 5824
51. 2 receptor J. Neurochem. 71 1998 799 807
52. 2 receptor Mol. Pharmacol. 57 2000 890 898
53. 2 receptors Proc. Natl. Acad. Sci. U. S. A. 93 1996 6802 6807
54. 2 dopamine receptors Br. J. Pharmacol. 121 1997 731 736
55. T. Takezako Network leaning" as a mechanism of insurmountable antagonism of the angiotensin II type 1 receptor by non-peptide antagonists J. Biol. Chem. 279 2004 15248 15257
56. 1A receptor mutants is blocked by inverse agonists J. Biol. Chem. 277 2002 5891 5901
57. R.J. Wilson Spontaneous contractions of myometrium from humans, non-human primate and rodents are sensitive to selective oxytocin receptor antagonism in vitro. BJOG 108 2001 960 966
58. D.J. Dupre Inverse agonist activity of selected ligands of the cysteinyl-leukotriene receptor 1 J. Pharmacol. Exp. Ther. 309 2004 102 108